Eton Pharmaceuticals offers GARP potential, focusing on ultra-rare disease drugs acquired at low cost, with a lean, specialized sales force and positive cash flow. My DCF model shows 80%-87% upside to ...

Eton Pharmaceuticals , Inc. (NASDAQ:ETON) has reached an all-time high, with its stock price soaring to $17.57. This milestone underscores a remarkable period of growth for the company, which has seen ...

Eton Pharmaceuticals has delivered strong growth through rare-disease drug launches, disciplined management, and successful product relaunches, driving triple-digit stock gains. ETON’s expanding ...

Investing.com -- Eton Pharmaceuticals Inc (NASDAQ:ETON) stock rose 3.9% Monday after the company announced it had licensed U.S. marketing rights to an ultra-rare disease product candidate that could ...

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big ...

Eton Pharmaceuticals (NASDAQ:ETON) just reported results for the second quarter of 2024. Eton Pharmaceuticals reported earnings per share of -12 cents. This was below the analyst estimate for EPS of ...